Background: Molecular imaging of carotid plaque vulnerability to atheroembolic events is likely to lead to improvements in selection of patients for carotid endarterectomy (CEA). The aims of this study were to assess the relative value of endothelial inflammatory markers for this application and to develop molecular ultrasound contrast agents for their imaging.
symptomatic patients. [2] [3] [4] [5] Treatment of patients with carotid atherosclerosis is limited by our ability to define individualized stroke risks on the basis of specific patient or carotid plaque characteristics. Thus, the number needed to treat to reduce one stroke during 5 years is 20. 2, 5 There is increasing interest in using noninvasive imaging to better identify which asymptomatic patients with carotid disease may benefit from surgical therapy. One promising strategy is to apply technologies for imaging that reveal the molecular or cellular profile of carotid plaques. Pathologic processes that have been associated with rapid plaque progression and susceptibility to atheroembolic events include plaque inflammatory burden, oxidative stress, protease activity, neovascularization, and loss of normal antiplatelet functions. 6, 7 Contrastenhanced ultrasound (CEU) is a promising technique for molecular imaging of plaque phenotype based on practical issues of cost, speed, and convenience. 8, 9 However, CEU relies on imaging of targeted microbubbles that are confined within the vascular space and cannot reveal interior plaque components. The aims of this study were to identify useful endothelial biomarkers that can differentiate plaque stability and to test clinically feasible microbubble targeting strategies for CEU. To accomplish our aims, specific immunohistochemistry (IHC) features of human CEA specimens from symptomatic vs asymptomatic subjects were compared. Microbubbles targeted to candidate markers were prepared using small molecular targeting moieties and surface conjugation strategies that are feasible for human use. Attachment efficiency was assessed by in vitro flow chamber experiments with cultured activated endothelial cells.
METHODS
CEA specimens. Studies were approved by the Institutional Review Board of the University of Arizona. CEA specimens from 30 consecutive asymptomatic and 30 consecutive symptomatic patients treated for carotid atherosclerotic disease between 2014 and 2017 were evaluated. We considered symptomatic patients to be those with transient ischemic attacks or strokes with motor or speech symptoms that were lateralizing to the contralateral side of the carotid lesion or amaurosis fugax on the ipsilateral side within 6 months of surgery; of note, all patients in this study had surgery within 4 weeks of symptoms. Patients operated on for atypical "symptoms" were excluded from the study. Patients who had no relevant symptoms within 6 months of surgery were considered asymptomatic. Specimens were fixed in formalin for 24 hours, transferred to 70% ethanol, and decalcified (ImmunoCal; Immunotech, Quebec, Canada). Plaques were partitioned lengthwise into w5-mm segments and embedded in paraffin on end to obtain cross sections sampled throughout the length of the plaque. Four partitions were embedded per block, requiring one or two blocks per plaque. Sections were cut to 4-mm thickness.
IHC. CEA sections were rehydrated with graded ethanol mixtures, and antigen retrieval was performed using a borate buffer for 60 minutes. IHC was performed in uniform fashion using the automated highthroughput Ventana Medical Stainer (Ventana Medical Systems, Tucson, Ariz) with monoclonal or polyclonal antibodies (Abcam, Cambridge, Mass) against human vascular cell adhesion molecule 1 (VCAM-1; ab106777), von Willebrand factor (vWF; ab6994), lectin-like oxidized low-density lipoprotein receptor 1 (LOX-1; ab60178), and P-selectin (ab135792). Staining was optimized using dilutions of 1:50, 1:100, and 1:200 in a Tris-based diluent (Ventana Medical Systems). After antigen retrieval using CC1 borate buffer at 100 C for 64 minutes (Ventana Medical Systems), the primary antibodies were added and the samples incubated for 60 minutes and then washed. The same antigen retrieval strategy was used for all samples. Peroxidase staining was performed using a diaminobenzidine detection kit (OptiView DAB kit; Ventana Medical Systems) that is an indirect, biotin-free system for detecting mouse immunoglobulin G, mouse immunoglobulin M, and rabbit primary antibodies. Detection was performed using an HQ Universal Linker (Ventana Medical Systems) and a horseradish peroxidase multimer. Hematoxylin II and bluing reagent were used for 4 minutes each for counterstaining. Samples were processed in one to three total groups (20-30 samples per group) to optimize standardization, with asymptomatic and symptomatic plaques processed as specimens were obtained. Each staining batch had positive control tissue stained simultaneously (human lymph node for VCAM-1 and P-selectin and normal human aorta for vWF and LOX-1). Optimization protocols resulted in the use of dilutions of 1:150, 1:100, 1:50, and 1:100 for VCAM-1, vWF, LOX-1, and P-selectin, respectively. IHC staining was evaluated by two independent physicians in a blinded fashion using 4Â, 10Â, and 20Â objectives. For grading purposes, a section was evaluated Recommendation: VCAM-1 may be a marker of activated endothelium in symptomatic carotid plaques and is a potential target for ultrasound imaging.
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from each segment (w5 mm) throughout the plaque (four to six sections per plaque). Antibody staining was quantified on a scale of 0 to 4 (0, minimal; 4, high) on the basis of intensity of endothelial staining. Uniform endothelial staining throughout all segments of plaque is not expected and was not observed; as such, the plaque was given the grade of the highest staining observed through the plaque. For example, if one section of the four to six sections evaluated had grade 4 but the others all had grade 1, the overall plaque grade was 4. Grading was done in batches to optimize uniformity of scale, and representative samples of each grade were available throughout the grading process for reference. Discrepancies in grading were discussed, and the two blinded physicians agreed on a single grade.
Microbubble preparation. Small peptide-targeting ligands with specific affinity for human VCAM-1, LOX-1, P-selectin, and vWF were prepared by NuvOx Pharma (Tucson, Ariz). [9] [10] [11] [12] The amino acid sequences for each of the targeting moieties are presented in Table I . Phospholipid-coated microbubbles entrapping perfluorocarbon gas were prepared. Lipids used in the formulation included dipalmitoylphosphatidylcholine, dipalmitoyl-sn-glycerophosphatidylethanolamine-polyethyleneglycol-2000-OMe (DPPE-MPEG2000) and a phospholipid-PEG2000-ligand bioconjugate composed of either DPPE-PEG2000-NH-linked to the ligand through a suberoyl linker or DPPE-PEG2000-C(¼O)-ligand linked through an amide bond. Control microbubbles contained DPPE-MPEG2000 in lieu of the phospholipid-PEG2000-peptide conjugate. A dissolved suspension of dipalmitoylphosphatidylcholine (90 mol%), DPPE-MPEG2000 (9 mol%), and phospholipid-PEG2000-linker-peptide conjugate (1%) was produced in propylene glycol at 50 C to 65 C. Dioctadecyl tetramethylindocarbocyanine was added to the suspension for fluorescent labeling of the microbubble shell. The warm solution of phospholipids in propylene glycol was then added in several aliquots to a solution of phosphate-buffered saline (PBS) containing 5% glycerol by volume with stirring at 50 C to 65 C; this solution was stirred 5 to 10 minutes. The solution was then transferred to a serum vial, which was immediately stoppered and crimp capped. The solution was allowed to come to ambient temperature and then stored at 4 C. A tranche of 25 to 50 2-mL nominal capacity serum vials were filled with 1.5-mL aliquots of the chilled phospholipid solution, followed by application of light vacuum and purging with perfluorobutane gas; those operations were followed by rapid stoppering and crimp capping of the vial. Vials were stored at 4 C until use, whereupon they were allowed to warm to ambient temperature and agitated on a VialMix apparatus (BristolMyers Squibb, Princeton, NJ) for 45 seconds at 75 Hz (4500 rpm) to form the microbubbles.
Flow chamber assessment of microbubble binding.
Human aortic endothelial cells (HAECs) were cultured with vascular cell basal medium (PCS-100-030; ATCC, Manassas, Va) and an Endothelial Cell Growth Kit-VEGF (PCS-100-041; ATCC). This growth kit included recombinant human vascular endothelial growth factor (5 ng/mL), recombinant human epidermal growth factor (5 ng/mL), recombinant human fibroblast growth factor basic (5 ng/mL), recombinant human insulin-like growth factor 1 (15 ng/mL), L-glutamine (10 mM), heparin sulfate Biotinylated peptides were designed to bind inflammatory molecules of interest. Peptide purity was $95% purity (reverse-phase high-performance liquid chromatography analysis). Mass/charge ratio is observed using electrospray mass spectrometry; M denotes the neutral peptide molecule, H denotes a proton, Na is a sodium cation, and K is a potassium cation.
(0.75 unit/mL), hydrocortisone (1 mg/mL), ascorbic acid (50 mg/mL), and fetal bovine serum (2%). HAECs used were primary cell lines for which all experiments were completed with no more than four passages. For experiments, HAECs were stained with 5 mL of calcein (green) dye and transferred to fibronectin-coated dishes. Calcein was used to evaluate the viability of the cells as it will stain only the cytoplasm of living cells. Culture dishes were mounted on a parallel plate flow chamber kit (Glycotech, Gaithersburg, Md) with a gasket thickness of 0.0254 cm and channel width of 0.25 cm. The parallel plate flow chamber was placed on an inverted microscope (Eclipse E600; Nikon, Tokyo, Japan) with a 40Â objective. The dioctadecyl tetramethylindocarbocyanine-labeled microbubbles were infused through the chamber with a peristaltic pump (Econo; Bio-Rad, Hercules, Calif) at a dilution of 1:1000 (microbubbles:volume of PBS). A variety of flow rates (mL/min) were tested, and the flow rate was converted to shear stress (dynes/cm 2 ). The flow rates tested ranged from 1.0 to 6.4 mL/min, which converted to shear stress ranging from 4.34 to 27.78 dynes/cm 2 , respectively.
Imaging was performed using low-level transillumination with fluorescent epi-illumination (Nikon Y-FL Statistical analysis. Regarding patient characteristics, group differences between asymptomatic and symptomatic patients were determined using a nonparametric Wilcoxon-Mann-Whitney test for the continuous data (age) and c 2 tests for categorical data. Fisher exact test was used in cases in which one of the cell sizes in frequency distribution was less than five. Differences between IHC staining were analyzed using the unpaired Student t-test. Analysis of microbubble binding to the HAECs was performed using two-sample Student t-tests assuming unequal variances. An a of <.05 was used for significance. All analyses were conducted using SAS version 9.4 (SAS Institute, Cary, NC).
RESULTS
Characteristics of the patients. A total of 60 CEA specimens were obtained from consecutive individuals who were symptomatic (30) and asymptomatic (30) . The demographic characteristics of the two different cohorts are presented in Table II . Symptomatic subjects had a greater prevalence of diabetes mellitus. Smoking and lack of antiplatelet therapy were more common in patients with symptomatic disease compared with asymptomatic disease, but this did not reach statistical significance.
CEA plaque molecular expression. CEA samples were processed in sequential order but stained in batches for standardization. Using antibodies specific for LOX-1 (1:50), P-selectin (1:100), vWF (1:100), and VCAM-1 (1:150), IHC staining of carotid specimens was performed to evaluate sections throughout the plaque (Fig 1) . Representative images of 40Â and 100Â magnification are shown for each antibody. There was minimal staining in the no-primary antibody control; although negative controls were run for each antibody, we show only one negative control sample because the IHC protocol for each antibody was identical. Although our focus was endothelial cell staining, staining with these antibodies throughout the intima and media was observed as expected. We noted robust vWF staining throughout all samples, mild LOX-1 staining throughout all samples, and variable VCAM-1 and P-selectin staining.
To quantify endothelium-specific expression, we evaluated expression using a semiquantitative scoring scale with a scoring range of 0 to 4. As noted, specimens were evaluated throughout the entire length of the plaque. Staining was assessed by two blinded experts as described in the Methods section. Representative examples of IHC for VCAM-1 and the semiquantitative scoring scale for endothelial staining are illustrated in Fig 2. We found a significantly greater degree of staining (P < .01) for endothelial VCAM-1 in plaques from symptomatic vs asymptomatic subjects (Fig 3) . Although endothelial staining of LOX-1, P-selectin, and vWF was present, there were no significant differences between the patient cohorts (Fig 3) . However, IHC does not necessarily differentiate P-selectin or vWF that is surface expressed from that which is stored within intracellular Weibel-Palade bodies. Expression of LOX-1 was relatively lower compared with other candidate molecules evaluated but similar between cohorts. Of particular importance in considering whether there may be an at-risk population of asymptomatic patients, we found that although VCAM-1 expression was significantly higher in symptomatic compared with asymptomatic patients, 22% of those with asymptomatic plaques had VCAM-1 staining scores of grade 2 or greater.
Targeted microbubble attachment to HAECs. Microbubbles targeted to each of the molecular epitopes present on atherosclerotic plaques in humans (VCAM-1, P-selectin, vWF, and LOX-1) using peptide ligands were prepared. HAECs that were used to test targeted microbubbles were consistently grown to confluence and were found to express the target molecules except P-selectin; level of expression was not quantified. For microbubble (IHC) staining for lectin-like oxidized low-density lipoprotein receptor 1 (Lox-1), Pselectin, von Willebrand factor (vWF), and vascular cell adhesion molecule 1 (VCAM-1). Carotid plaques were evaluated by IHC using antibodies specific for Lox-1 (1:50), P-selectin (1:100), vWF (1:100), and VCAM-1 (1:150) as described in the Methods section. Representative images of each are shown in either 40Â or 100Â magnification. Control images show IHC with no primary antibody used; as staining protocols were the same for all four antibodies, we show only one representative control image. L indicates the carotid lumen in each section. The black bars represent 500 mm in 40Â images and 100 mm in 100Â images.
binding quantification, flow chambers were used with plated HAECs, and bound microbubbles were counted under varying mechanical shear stress conditions (experiments were repeated three to five times per point). Irrespective of the shear stress, there was not permanent attachment of control nontargeted microbubbles (Fig 4) . At low shear stress that is typically found in the larger microcirculation (4-5 dynes/cm 2 ), attachment occurred for all targeted agents, although attachment was greatest for VCAM-1-targeted microbubbles (P < .05). Attachment efficiency decreased with increased shear stress for all agents but remained higher for VCAM-1. At high continuous shear stress like that found in the human carotid artery (>20 dynes/cm 2 ), attachment was observed only for VCAM-1-targeted microbubbles.
DISCUSSION
The current approach for selecting patients with asymptomatic carotid vascular disease for surgical intervention is based largely on randomized trials performed more than a decade ago (Asymptomatic Carotid Atherosclerosis Study [ACAS] , Asymptomatic Carotid Surgery Trial 1 [ACST-1]). 2, 3, 5 There remains significant controversy as to whether asymptomatic patients with carotid atherosclerosis benefit from CEA. Accordingly, there is Vascular cell adhesion molecule 1 (VCAM-1) expression differentiates carotid plaques from asymptomatic vs symptomatic patients. Carotid plaques from symptomatic (S) and asymptomatic (A) patients were evaluated by immunohistochemistry (IHC) using antibodies specific for (A) VCAM-1, (B) P-selectin, (C) lectin-like oxidized low-density lipoprotein receptor 1 (Lox-1), and (D) von Willebrand factor (vWF). Endothelial staining intensity was graded blindly by two observers (per grading scale seen in Fig 2) . Graphs show mean staining intensity; error bars represent standard deviation; P values were calculated using nonpaired Student t-test.
interest in the creation of noninvasive approaches using blood tests and imaging that add predictive information on risk of future atheroembolic events to basic information of percentage stenosis of the internal carotid artery and symptomatic status. The lack of accounting for the patient's genetics, carotid plaque molecular expression profiles, or even advanced imaging techniques indicates the need for improvements in both diagnosis and treatment of this disease. Preclinical and clinical studies have suggested that novel forms of diagnostic imaging could aid in stratifying patients for stroke risk. Plaque assessment by magnetic resonance imaging (MRI) has been a popular approach owing to the ability to use different imaging sequences to discern plaque composition. MRI has been used to detect the presence of intraplaque hemorrhage (IPH) as well as to differentiate between fibrous and fatty or necrotic plaques. Aside from cost, there are some drawbacks in the MRI diagnosis of IPH to select high-risk patients with asymptomatic carotid vascular disease. Based on our data (unpublished) and those of others, 14, 15 50% to 85% of patients with asymptomatic carotid disease have IPH on histologic evaluation. Some studies find no difference in IPH presence in plaques from symptomatic and asymptomatic patients. Other experimental imaging modalities that bear mentioning include MRI evaluation for prior subclinical events, 16, 17 transcranial Doppler ultrasound to detect microemboli, 18 and various strategies of plaque characterization with ultrasound tissue characterization or vasa vasorum detection. 19 Larger trials evaluating these experimental technologies will be needed to validate the widespread adoption of these new technologies. A more accurate method for evaluating susceptibility to atheroembolic events and selection for surgical management could be to image the molecular events that predispose to plaque instability. The potential targets for this purpose are broad and include endothelial activation, plaque inflammatory cell content or activity, protease activity, apoptosis, and oxidative lipid accumulation. 20, 21 Clinical studies have been performed primarily with 18 F-fluorodeoxyglucose positron emission tomography as a putative marker for plaque inflammatory activity. 22 CEU methods that have been developed are based on the idea of targeting intravascular events at the plaque surface that provide information on the presence of more unstable plaque. 23 These markers include expression of endothelial cell adhesion molecules that are responsible for monocyte recruitment (VCAM-1, selectins, intercellular adhesion molecule 1), thrombosis-related factors (platelets, dysregulated vWF, fibrin, tissue factor), LOX-1, and general markers of endothelial activation or angiogenesis. [24] [25] [26] [27] [28] The primary purpose of this study was to assess the relative endothelial expression profile on human carotid plaque of some of the targets that have appeared most promising in preclinical studies for defining high-risk plaques. Other groups have performed similar experiments to evaluate human carotid plaque molecular expression profiles, but we have seen no data for evaluation for endothelial expression of the markers we believed were most promising. 29, 30 Of the four candidate molecules evaluated, VCAM-1 was the most useful to differentiate high-risk (symptomatic) vs low-risk (asymptomatic) carotid plaques (P < .01). This contradicts Schneiderman et al because they found similar or lower VCAM-1 expression in symptomatic plaques; however, their manuscript does not show VCAM-1 staining for evaluation, they do not evaluate the full carotid plaque, and most important, they were evaluating total VCAM-1 expression as opposed to only endothelial expression. 31 vWF had the highest expression in carotid plaque endothelium but did not differentiate between plaques from symptomatic and asymptomatic patients. Although P-selectin, vWF, and LOX-1 have key roles in atherosclerotic plaque biology, our data indicate that these molecules do not differentiate high-risk from low-risk carotid plaques in humans on the basis of endothelial expression. However, IHC does not necessarily reflect the activated molecular form of vWF that targeted microbubbles bind in vivo. 24 Our data also show that although most carotid plaques from asymptomatic patients have low (grade 0 or 1) VCAM-1 expression, 22% have moderate or high expression (grade 2-4). This is key because if all plaques from asymptomatic patients had low expression, there would be no potential utility of VCAM-1 expression to identify asymptomatic patients who may be at higher risk for atheroembolic events similar to symptomatic patients. These IHC-based studies are limited by their quantification methodology. Although staining classification was done in a fully blinded fashion with multiple steps to ensure full and consistent evaluation throughout the process, the grading methodology is still based on a subjective scale. An alternative would have been quantification with immunofluorescence measurement. However, because the candidate molecule expression is not limited to the blood vessel endothelium, expression would still need to be quantified with significant human input. As such, we did not see a benefit of immunofluorescence over IHC. In addition, we think that plaque specimen processing and full-length evaluation are more reproducible using IHC methodology. These experiments are also limited because no in vivo carotid plaque imaging in humans could be done, and we have no way in this study to know whether VCAM-1 or the other markers will be predictive of atheroembolic events. Detection of VCAM-1 expression in asymptomatic plaques as a marker of high-risk phenotype, however, is intriguing. Prospective human studies will be needed to determine whether VCAM-1 expression correlates with increased risk of subsequent atheroembolic events in patients who present with asymptomatic disease.
Prior strategies for localizing endothelial molecules with ultrasound contrast have used immunoglobulin protein for microbubble targeting, which can be of limited utility in humans secondary to immunoreactivity. We created ultrasound contrast agents using peptides shown to be specific for VCAM-1 and other candidate biomolecules. [9] [10] [11] [12] Our data show that VCAM-1-targeted microbubbles bind human endothelial cells under shear conditions that approximate those found in the human carotid artery. Decreased binding of other targeted microbubbles could be from differential target expression on HAECs or peptide-ligand binding efficiency, but these hypotheses were not tested. Although decreased binding of microbubbles observed with increased shear stress could be secondary to changes in endothelial molecular expression profiles, we believe it is more likely that binding efficiency of microbubbles decreases with the increased shear. 32 Although our data indicate that vWF and LOX-1 expression did not differentiate highrisk from low-risk plaques, these targeted microbubbles may prove useful for studying development of atherosclerosis in animal models. These experiments are limited because of their in vitro nature and lack of evaluation for binding efficiency and specificity. As such, our proof-of-concept experiments will need further investigation. Utility of these agents for detection of murine endothelial expression patterns in atherosclerosis models will need to be evaluated, and further preclinical trials are needed before their usefulness in humans can be determined.
CONCLUSIONS
Our data are the first to show that VCAM-1 is significantly upregulated in symptomatic vs asymptomatic carotid plaques from humans. It may be that VCAM-1 expression represents a more sophisticated, biomolecular-based method to categorize high-risk carotid plaques. These data, if corroborated by others, are potentially major contributions to the field because they confirm molecular pathways associated with plaque instability and represent a promising molecular target for diagnostic, personalized medicine. Furthermore, our data are also the first to show that peptide-bearing targeted, clinically translatable microbubbles are tools for the study of dysfunctional vascular endothelium and hold a great potential to help differentiate high-risk from low-risk plaques in vivo. This imaging strategy would include a simple intravenous injection of an ultrasound contrast agent and evaluation of carotid plaque with duplex ultrasound. Such noninvasive imaging could greatly improve selection of patients for surgical intervention, resulting in improved cost-benefit ratios and prevention of associated morbidity and mortality of unneeded operations.
